As reported in The
New York Times, "Lung Cancer Deaths are Reduced
by CT Scans." The challenge with CT, as reported in
recent NCI data, is the 25 percent false positive
rate.
EarlyCDT™-Lung is
a blood test which can be used in congruence with
CT to aid in risk assessment and early detection of lung
cancer in high-risk patients or patients with a lung
nodule under surveillance; a
positive result can increase malignancy risk by
5-fold.
Benefits of EarlyCDT™-Lung:
|
· 3
times better
Positive Predictive Value than CT
· 7
times fewer
false positives than CT
· Detects all
types and all
stages of
lung cancer, including Stage
1
· Is reimbursed by
Medicare Part B and private insurance
Learn more about EarlyCDT™-Lung
|
|
EarlyCDT™-Lung is
a simple blood test based on a panel of autoantibodies,
which arise early in the development of lung cancer.
To
bring more recognition to November, National Lung Cancer
Awareness Month, Oncimmune released Hello,
Have You Heard?,
a reliable source of information for your patients. The
site provides current information on lung cancer, early
detection and other related topics. |
Hello
have you heard?
Hello
have you heard?